Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression
Eli Lilly (United States) · Harvard University Press · +7 more institutions
Indexed incrossrefpubmed
Abstract
Background
Despite the longer duration of the depressive phase in bipolar disorder and the frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for bipolar depression.
Objective
To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Citation impact
908
total citations
- FWCI
- 35.86
- Percentile
- 100%
- References
- 52
Citations per year
Authors
15Topics & keywords
Topics
Keywords
- Olanzapine
- Fluoxetine
- Mania
- Young Mania Rating Scale
- Placebo
- Psychology
- Randomized controlled trial
- Psychiatry
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- JDJohn D. and Catherine T. MacArthur Foundation
- ALAbbott Laboratories
- ELEli Lilly and Company
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- MGMassachusetts General Hospital
- TPTeva Pharmaceutical Industries
- MHMcLean Hospital
- UOUniversity of Pittsburgh
- CWCase Western Reserve University
- UOUniversity of New South Wales
- MCMedical Center, University of Pittsburgh
- NINational Institute of Mental Health
- UPUCB Pharma
- CCilag